Jan-Nygaard Jensen, global head of computational biology and digital science at Boehringer Ingelheim GmbH, says the German pharma is focused on a longer-term view to use artificial intelligence and big data applications to de-risk drug development so that it is less resource-intensive and time-consuming.
Boehringer De-Risking Development With Computational Biology
Obtaining useful biological information from the enormous amount of health data available could reduce attrition rates, accelerate development timelines and optimize trial design.
